Introduction
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is characterized by a large heterogeneity in symptoms, severity and treatment response. It has been suggested that this may be due to differences in pathophysiological and etiological mechanisms (Aslakson et al., 2009) . ME/CFS is characterized by longstanding unclear fatigue interfering with functioning (personal, social and work-related disability) (2). Importantly, patients present with an array of additional recurrent flu-like symptoms pertaining to immune activation (e.g. malaise, tender lymph nodes and feverishness), as well as musculoskeletal pain and neurocognitive impairment (Carruthers et al., 2003) .
So far, no consistent illness-specific findings have been shown in clinically used inflammatory markers, such as erythrocyte sedimentation rate or C-reactive protein. However, currently used clinical tests may fail to detect pathophysiological processes in ME/CFS such as neurological infections and inflammation (Davis and Tyler, 2005; Ghose et al., 2019) and an increasing number of studies show various https://doi.org/10.1016/j.psyneuen.2019.104578 Received 5 July 2019; Received in revised form 4 December 2019; Accepted 20 December 2019 imbalances in levels of cytokines in ME/CFS, both in blood and in cerebrospinal fluid (Hornig et al., 2016 (Hornig et al., , 2015 Montoya et al., 2017; Russell et al., 2016) . In a recent study by Montoya et al., a significant relationship between high levels of inflammatory markers and fatigue severity in ME/CFS was found, however more research is needed to investigate if and for whom longstanding low-grade inflammatory processes are related to symptoms in ME/CFS (Montoya et al., 2017) . Furthermore, there is a scarcity of studies investigating the relationship between low-grade inflammation and other primary symptoms in ME/ CFS besides fatigue.
The interaction between the immune system and the brain might contribute to the understanding of symptom variation in ME/CFS. In short, when the immune system is activated, inflammatory cytokines are released and soon the afflicted person will present with sickness behavior such as fatigue, malaise, anxiety, anhedonia, worsened mood, reduced social interaction and increased pain sensitivity (Dantzer et al., 2008) . The sickness behavior response has been considered a key mechanism in the recovery from acute illness, while persistent sickness behavior may contribute to the debilitating symptoms in some patients with ME/CFS. To date, the relationships between low-grade inflammation and the commonly reported post-exertional, flu-like, musculoskeletal and neurocognitive symptoms in ME/CFS are still unclear.
The aim of this study was to preliminarily explore the association between inflammatory markers and common symptoms in ME/CFS. Specifically, we wanted to investigate (a) the association between sickness behavior-related inflammatory markers and recurrent flu-like symptoms in ME/CFS, and (b) the associations between inflammatory markers previously shown to be related to fatigue severity in ME/CFS and common ME/CFS symptoms post-exertional fatigue, impaired cognitive processing and musculoskeletal pain, and (c) the moderating effect of biological sex on these associations, as there is a lack of studies in ME/CFS research exploring sex differences. We also wanted to provide data on inflammatory markers and symptoms as a supplement in order to enable analyses on the relationships between inflammatory markers and symptoms in ME/CFS in larger materials with data from multiple research groups and studies.
Methods

Participants and procedure
53 adult patients diagnosed with ME/CFS were included in the study. Participants were recruited consecutively as part of the diagnostic assessment at a tertiary specialist clinic after referral, from 2013 to 2016, as described previously (Jonsjö et al., 2019) . After referral, participants were assessed by a physician and a psychologist in order to exclude other potential causes for symptomatology. Patients were excluded from the study if: (a) somatic comorbidity which could explain symptomatology was present; (b) they were non-adherent during the assessment phase; (c) they did not speak Swedish; (d) they had ongoing treatment known to modulate immune functioning; (f) they had psychiatric comorbidity meeting criteria for schizophrenia, bipolar disorder or major depressive disorder. All participants fulfilled the 1994 CDC and 2011 ICC criteria for ME/CFS. All participants presented with longstanding unexplained fatigue, post-exertional malaise and symptom exacerbation as well as prolonged recovery period after even mild to moderate mental, physical or emotional effort. The study was approved by the Regional Ethical Review Board in Stockholm, Sweden (Dnr 2015/370-31/4) and all participants gave written informed consent.
Measures
Inflammatory markers
Blood samples were taken at the Karolinska University Hospital Solna laboratory in the morning, between 8 a.m. and 12 a.m., after an overnight fast. Samples were stored in room temperature before centrifugation at 2000 rpm for 10 min, and was stored at -70 degrees Celsius until analyses. Blood plasma was analyzed using the Olink Proseek Multiplex Inflammation panel measuring 92 different analytes (Olink, Uppsala, Sweden).
For this study, 13 inflammatory markers were chosen based on previous research. Three sickness behavior-related inflammatory markers (tumor necrosis factor (TNF)-α, interleukins (IL)-6 and (IL)-8) and 10 inflammatory markers previously shown to be related to fatigue severity in ME/CFS; IL-7, IL-10, IL-18, Eotaxin (CCL11), C-X-C motif chemokine (CXCL)1, CXCL10, Latency-associated peptide transforming growth factor beta (LAP-TGF-β)-1, Transforming growth factor (TGF)α, Stem cell factor (SCF) and Beta-nerve growth factor (β-NGF) were included. The Human Cytokine Type 1 assay (BioRad, Hercules, CA, USA) was used to ascertain levels of TNF-α as this marker was not detected in half of the samples using the Olink panel. All other markers had adequate detectability.
ME/CFS symptoms & illness duration
Data on illness duration and symptoms were collected as part of the visit to the ME/CFS specialist clinic. A structured clinical interview with each participant was carried out by a senior physician. As part of the interview, participants rated the average severity of symptoms, based on the 2011 International Consensus Criteria (Carruthers et al., 2011) , on a numerical rating scale from 0 (not present) to 10 (worst imaginable level). Patients also reported duration of the illness, which was cross-referenced through medical records. Symptoms were selected based on (a) sickness behavior similarity (recurrent flu-like symptoms, i.e. general malaise) and (b) previous ME/CFS research and our clinical experience of the symptoms reported by patients as most debilitating (post-exertional fatigue; impaired cognitive processing, i.e. slowed thought and difficulty concentrating, and; musculoskeletal pain).
Statistical analyses
All data were analyzed using SPSS version 25 (IBM Corp. IBM SPSS statistics for Macintosh, version 25. Armonk, NY: IBM Corp, 2017). Patient characteristics, inflammatory markers and symptoms were analyzed using descriptive statistics. Bivariate Spearman correlations were utilized for investigating (a) the association between sickness behavior-related inflammatory markers (TNF-α, IL-6 and IL-8) and recurrent flu-like symptoms and; (b) the association between inflammatory markers implicated in ME/CFS (IL-7, IL-10, IL-18, CCL11, CXCL1, CXCL10, LAP-TGF-beta-1, TGF-α, SCF and β -NGF) and postexertional fatigue, impaired cognitive processing and musculoskeletal pain. The participants biological sex was explored as a moderator of the association between inflammatory markers (predictor) and symptoms (outcome) using the PROCESS SPSS Macro version 3.3, model 1, for moderated regression analyses bootstrapped with 5000 repetitions (Hayes, 2018) . Inflammatory markers were standardized so that the coefficient corresponds to the difference in symptom rating between two subjects whose levels of inflammatory marker differ by 1 SD (hereafter referred to as b coefficient).
Data on all inflammatory markers from the Olink panel, BioRad data on TNF-α and reported symptom ratings are provided as supplementary information accompanying this paper at the Dryad data repository (https://doi.org/10.5061/dryad.f1vhhmgsb).
Results and discussion
Participants (mean age 48.1 years, SD 10.4) were mainly women (66.1 %), with a mean illness duration of 12.2 (SD = 7.6) years. Higher levels of TNF-α was significantly associated with recurrent flu-like symptoms (mean = 6.2, SD = 2.6; Spearman's ρ = 0.38, p < .01; Moderated regression analysis independent of sex b = 0.74, p = .01), an association that was not moderated by sex (b=0.20, p = .78). This is M.A. Jonsjö, et al. Psychoneuroendocrinology 113 (2020) 104578 consistent with previous studies in the sickness behavior literature, for example in experimental studies where elevations of pro-inflammatory cytokines and sickness symptoms after stimulation of the immune system are repeatedly demonstrated (Dantzer et al., 2008) . No significant associations were seen between IL-6 (ρ=-0.20, p = .18; b=-0.56, p = .09) and IL-8 (ρ = 0.07, p = .64; b = 0.19, p = .60) and flulike symptoms.
Higher levels of β-NGF was significantly associated with post-exertional fatigue (Table 1 and 2), in both men and women. Sex moderated the association between CXCL10 and post-exertional fatigue ( Table 2) . Further analysis demonstrated a significant negative relationship for women (b=-0.89, p = .05) and a non-significant positive relationship for men (b=0.82, p = .11). Higher levels of β-NGF and CCL11 were significantly associated with impaired cognitive processing, no moderation by sex was found for these associations (Table 2) . Notably, for musculoskeletal pain, IL-7 and TGF-β both demonstrated significant main and interaction effects ( Table 2) . Further analyses showed a significant association between higher levels of the markers and higher pain only for men (b IL-7 =4.25, p < .01 and b TGF-β =2.71, p < .001), indicating potential differences in the effect of low-grade inflammation for musculoskeletal pain between women and men in ME/CFS. Higher levels of β-NGF was associated with more musculoskeletal pain without evidence for a moderation effect of sex (Table 2) .
Comparing results from studies investigating levels of inflammatory markers is difficult, as variation in levels of cytokines in peripheral blood can be affected by several factors including behavior, sleep, BMI, smoking, time of day and method of analysis (Nilsonne et al., 2016; VanElzakker et al., 2019) . There is a lack of studies investigating the association between inflammatory markers and common symptoms, other than fatigue, in the ME/CFS patient population. In contrast to the study by (Montoya et al. (2017) , we found only one significant association between inflammatory markers, β-NGF, and severity of postexertional fatigue. In the present study, average severity of post-exertional fatigue was used as a single measure. In the Montoya study, total scores on the MFI-20 were used to classify patients in fatigue severity groups (mild; moderate; severe), and the use of different measures of Table 1 Spearman correlations between inflammatory markers previously shown to be related to fatigue severity in ME/CFS and symptoms. Table 2 Moderated regression analyses of inflammatory markers previously shown to be related to fatigue severity in ME/CFS and symptoms. fatigue make comparisons between the studies difficult (Montoya et al., 2017) . Furthermore, the natural variation of cytokines in peripheral blood may also explain the lack of associations. In addition, the relatively low power in the present study might have led to associations being missed. The present study is limited regarding the cross-sectional design, small sample size likely leading to type II errors, and large number of inflammatory markers measured. It should be noted that the analyses are not adjusted for multiple comparisons, and several of the findings are likely due to type 1 errors, why the results should be interpreted with caution until replicated in future studies. Patients in the present study had a relatively high degree of functioning on the ME/CFS spectrum (i.e. not homebound) which could reduce the variance in inflammatory markers and symptoms. Future studies on relations between low-grade inflammation and key symptoms in ME/CFS should investigate dimensions of fatigue and other symptoms of high relevance to ME/CFS as multifaceted phenomena that may vary both between and within individuals (Karshikoff et al., 2017) . Furthermore, diverging results may indicate that ME/CFS consists of a heterogenous illness population, and longstanding low-grade inflammation may have a differential influence on symptoms across individuals. A longitudinal study with multiple measurements will improve investigations of inflammatory markers and their importance for symptom development in ME/CFS. In order to identify potential disease phenotypes, there is a need to build large materials with data from multiple studies, including data on illness duration which has been implicated as important for the variation of inflammatory markers in ME/CFS (Hornig et al., 2015) . We anticipate that the data from the present study will be used by other researchers for this purpose.
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